Furukawa K S, Furukawa K, Real F X, Old L J, Lloyd K O
Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
J Exp Med. 1989 Feb 1;169(2):585-90. doi: 10.1084/jem.169.2.585.
Analysis of antibodies present in the serum of melanoma patient FD has shown that they detect a unique tumor epitope present only on the autologous melanoma cell line SK-MEL-131. Previous results had shown that the unique FD epitope is carried on a common glycoprotein of approximately 90 kD, widely expressed on melanoma and a few other cell types. We now show by sequential radioimmunoprecipitation and partial amino acid sequencing that this common molecule is a previously recognized melanoma antigen, originally identified by mouse mAbs, designated gp95 or p97 (and also known as melanotransferrin). Thus, FD is the first of the class I (unique) melanoma antigens that has been characterized and related to a known cell surface molecule.
对黑色素瘤患者FD血清中存在的抗体进行分析表明,这些抗体能检测到仅存在于自体黑色素瘤细胞系SK-MEL-131上的独特肿瘤表位。先前的结果表明,独特的FD表位存在于一种约90kD的常见糖蛋白上,该糖蛋白在黑色素瘤和其他一些细胞类型中广泛表达。我们现在通过连续放射免疫沉淀和部分氨基酸测序表明,这种常见分子是一种先前已识别的黑色素瘤抗原,最初由小鼠单克隆抗体鉴定,命名为gp95或p97(也称为黑素转铁蛋白)。因此,FD是已被鉴定并与已知细胞表面分子相关的I类(独特)黑色素瘤抗原中的首个抗原。